ABCELLERA BIOLOGICS INC

NASDAQ: ABCL (AbCellera Biologics Inc.)

Last update: 9 hours ago

2.41

-0.08 (-3.21%)

Previous Close 2.49
Open 2.52
Volume 3,261,534
Avg. Volume (3M) 4,162,235
Market Cap 719,201,856
Price / Sales 24.81
Price / Book 0.680
52 Weeks Range
1.89 (-21%) — 4.34 (80%)
Earnings Date 8 May 2025
Operating Margin (TTM) -807.03%
Diluted EPS (TTM) -0.550
Quarterly Revenue Growth (YOY) -45.00%
Total Debt/Equity (MRQ) 6.19%
Current Ratio (MRQ) 9.81
Operating Cash Flow (TTM) -108.56 M
Levered Free Cash Flow (TTM) -177.77 M
Return on Assets (TTM) -12.41%
Return on Equity (TTM) -14.75%

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Mixed
Biotechnology (Global) Mixed Mixed
Stock AbCellera Biologics Inc. Bearish Bearish

AIStockmoo Score

1.6
Analyst Consensus 3.0
Insider Activity NA
Price Volatility 0.5
Technical Moving Averages 1.0
Technical Oscillators 2.0
Average 1.63

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
ABCL 719 M - - 0.680
AKRO 4 B - - 4.77
SPRY 1 B - 174.63 5.32
REPL 771 M - - 1.54
SAGE 467 M - - 1.02
ZVRA 437 M - - 9.93

AbCellera Biologics Inc is an antibody discovery and development engine that’s specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company’s experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

Sector Healthcare
Industry Biotechnology
Investment Style Small Value
% Held by Insiders 22.88%
% Held by Institutions 42.28%

Ownership

Name Date Shares Held
Baker Bros. Advisors Lp 31 Dec 2024 27,525,640
Baillie Gifford & Co 31 Dec 2024 12,236,465
Voya Investment Management Llc 31 Dec 2024 10,624,185
Capital World Investors 31 Dec 2024 7,933,613
Orbimed Advisors Llc 31 Dec 2024 4,180,768
Arrowmark Colorado Holdings Llc 31 Dec 2024 4,105,095
Two Sigma Investments, Lp 31 Dec 2024 3,257,311
Two Sigma Advisers, Lp 31 Dec 2024 2,608,400
Guardian Capital Advisors Lp 30 Sep 2024 1,786,414
52 Weeks Range
1.89 (-21%) — 4.34 (80%)
Price Target Range
5.00 (107%) — 10.00 (314%)
High 10.00 (Stifel, 314.94%) Buy
Median 7.50 (211.20%)
Low 5.00 (Keybanc, 107.47%) Buy
Average 7.50 (211.20%)
Total 2 Buy
Avg. Price @ Call 2.49
Firm Date Target Price Call Price @ Call
Keybanc 16 Apr 2025 5.00 (107.47%) Buy 2.39
Stifel 28 Feb 2025 10.00 (314.94%) Buy 2.59

No data within this time range.

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria